I DERM Pharma is a biotech company developing a first-in-class oral small-molecule therapy for the treatment of moderate-to-severe psoriasis.

Our lead program aims to bridge the gap between highly effective biologics and existing oral therapies by combining strong efficacy with the convenience of oral administration and a favorable safety profile. The program is supported by compelling preclinical efficacy data in humanized models of psoriasis and is being advanced toward clinical development.

Operating in a large and rapidly growing moderate-to-severe psoriasis market, I DERM Pharma is progressing its lead candidate through IND-enabling studies with a clear roadmap toward clinical proof of concept. The company is building on strong market validation from recent pharmaceutical acquisitions in oral immunology and a robust intellectual property strategy.

I DERM Pharma is focused on developing differentiated oral therapies for chronic inflammatory and autoimmune diseases and is actively engaging with strategic partners and investors to accelerate development.

I Derm Pharma

Org chart

Teams

Offices